The sBLA submission included results from the randomized, parallel-arm, placebo-controlled and active-controlled trial foresiGHt.

Number of people with at least one episode of HSV-attributable genital ulcer disease was 187.9 and 16.7 million for HSV-2, HSV-1 in 2020 ...

Findings seen among children and adolescents with type 1 diabetes and nonoptimal control with traditional treatment ...

A higher risk of liver transplant and death was observed in Ocaliva-treated patients vs those who received placebo.

(HealthDay News) — Adults receiving chiropractic spinal manipulative therapy (SMT) for tension-type headache have a significantly lower likelihood of butalbital prescription, according to a study ...

The burden of respiratory syncytial virus (RSV) in young children continues to be high in the United States, according to a study published online Dec. 9 in JAMA Pediatrics. Heidi L. Moline, MD, MPH, ...

A Prescription Drug User Fee Act target date of July 24, 2025 has been set for the sNDA application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) ...

Interim data from a phase 3 study evaluating tecovirimat for the treatment of human mpox virus showed the antiviral did not improve time to lesion resolution compared with placebo.

(HealthDay News) — Vitamin D 3 supplementation does not significantly reduce the risk for developing diabetes among older adults who are not at high risk for diabetes, according to a study published ...

Screening recommended every three years with cervical cytology for women aged 21 to 29 years, every five years with hrHPV screening at age 30 to 65 years ...

Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...

The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.